This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Tricida Crecimiento futuro
Future controles de criterios 0/6
Información clave
57.3%
Tasa de crecimiento de los beneficios
58.1%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 22.3% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 29 Mar 2023 |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2023 | N/A | -58 | -29 | -29 | 1 |
| 12/31/2022 | N/A | -109 | -89 | -89 | 1 |
| 9/30/2022 | N/A | -134 | -109 | -109 | N/A |
| 6/30/2022 | N/A | -148 | -119 | -119 | N/A |
| 3/31/2022 | N/A | -153 | -136 | -135 | N/A |
| 12/31/2021 | N/A | -177 | -140 | -140 | N/A |
| 9/30/2021 | N/A | -181 | -145 | -144 | N/A |
| 6/30/2021 | N/A | -219 | -177 | -176 | N/A |
| 3/31/2021 | N/A | -244 | -212 | -211 | N/A |
| 12/31/2020 | N/A | -265 | -233 | -231 | N/A |
| 9/30/2020 | N/A | -268 | -220 | -219 | N/A |
| 6/30/2020 | N/A | -235 | -202 | -201 | N/A |
| 3/31/2020 | N/A | -213 | -158 | -157 | N/A |
| 12/31/2019 | N/A | -177 | -131 | -130 | N/A |
| 9/30/2019 | N/A | -146 | -134 | -133 | N/A |
| 6/30/2019 | N/A | -131 | -119 | -118 | N/A |
| 3/31/2019 | N/A | -120 | -104 | -104 | N/A |
| 12/31/2018 | N/A | -103 | -96 | -95 | N/A |
| 9/30/2018 | N/A | -96 | -79 | -78 | N/A |
| 6/30/2018 | N/A | -77 | -60 | -58 | N/A |
| 3/31/2018 | N/A | -60 | -49 | -47 | N/A |
| 12/31/2017 | N/A | -41 | -41 | -40 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: 1T7 is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: 1T7 is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: 1T7 is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if 1T7's revenue is forecast to grow faster than the German market.
Ingresos de alto crecimiento: 1T7 is forecast to have no revenue next year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 1T7's Return on Equity is forecast to be high in 3 years time